Catalyst Dossier · compiled by CeliA 🧫

Longeveron Inc. (LGVN)

Pharmaceutical Preparations · market cap $16M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-31

Data Readout

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Longeveron Inc. (LGVN) is a clinical-stage cell therapy company with a $16M market cap and 38 employees, developing Lomecel-B (medicinal signaling cells) and mesenchymal stem cell (MSC) platforms across multiple Phase 2 indications including Hypoplastic Left Heart Syndrome (HLHS), Aging Frailty, and Mild Alzheimer's Disease. The company has ~10.8 months of cash runway on $15.8M in cash, burns roughly $20M+ per year, and faces a data readout catalyst flagged for August 31, 2026. Revenue is negligible (~$1-2M annually), and the company has posted consistent net losses of $16-23M per year.

The catalyst path

2026-08-31Data Readoutimp 5/10

Pipeline

Asset	Phase	Indication
Lomecel-B medicinal signaling cells	Phase 2	Hypoplastic Left Heart Syndrome
Fluzone High Dose Vaccine	Phase 2	Aging Frailty
Allogeneic MSC	Phase 2	Mild Alzheimer's Disease
Longeveron Mesenchymal Stem Cells (LMSCs)	Phase 2	Aging Frailty
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)	Phase 2	Frailty

Price & technical context

3-month

-14.0%

6-month

+30.8%

12-month

-54.8%

52-wk range

$0.48–$1.71

vs 50-day MA

+2.8%

vs 200-day MA

+0.6%

Realized vol

113.3%

Max drawdown

-89.4%

Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for LGVN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.